Does systemic inflammation promote small, dense LDL and impair HDL function?

Systemic inflammation significantly alters lipid metabolism, transforming standard lipoproteins into more atherogenic and dysfunctional forms. These changes occur even when traditional lipid panels, such as total LDL or HDL cholesterol, appear within normal ranges, making the inflammatory state a critical driver of cardiovascular risk.

Effects on LDL particle size and density

Systemic inflammation actively promotes the formation of small, dense LDL (sdLDL), a subclass characterized by increased arterial wall penetration and a higher susceptibility to oxidation.

• Enzymatic Remodeling: Cytokines like IL-6 and TNF-α stimulate the hepatic production of C-reactive protein (hs-CRP) and upregulate Cholesteryl Ester Transfer Protein (CETP). CETP facilitates the exchange of cholesteryl esters from LDL for triglycerides from VLDL.
• Particle Shrinkage: Hepatic Lipase (HL) then hydrolyzes the triglycerides and phospholipids on these enriched LDL particles. This process reduces the particle size and increases its density, resulting in the sdLDL phenotype.
• Atherogenic Potential: These smaller particles have a lower affinity for the LDL receptor, increasing their circulation time and likelihood of becoming trapped in the subendothelial space, where they trigger further inflammatory responses.

Impairment of HDL structure and function

Inflammation triggers a "proteomic shift" in HDL, converting it from a protective, anti-inflammatory particle into a dysfunctional or even pro-inflammatory one.

• Structural Displacement: During acute or chronic inflammatory states, Serum Amyloid A (SAA) is upregulated and displaces Apolipoprotein A-I (ApoA-I), the primary structural protein of healthy HDL. This displacement fundamentally changes the particle's molecular composition.
• Functional Decline: The loss of ApoA-I and the accumulation of SAA lead to a marked reduction in cholesterol efflux capacity (CEC), the essential process by which HDL removes excess cholesterol from macrophages in the arterial wall.
• Loss of Antioxidant Capacity: Inflammation suppresses HDL-associated enzymes such as paraoxonase-1 (PON1) and lecithin-cholesterol acyltransferase (LCAT). Furthermore, myeloperoxidase (MPO) activity during inflammation oxidizes HDL lipids and proteins, impairing its ability to prevent LDL oxidation.

Bottom line

Systemic inflammation promotes the formation of highly atherogenic small, dense LDL particles and impairs HDL function by displacing essential proteins like ApoA-I with SAA, effectively neutralizing HDL's protective role in cholesterol transport and antioxidant defense.